NCT01040000 - QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Metastatic Pancreatic CancerMetastatic Colorectal Cancer

Interventions

DRUG

NPC-1C/NEO-102

Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.

Trial Locations (6)

21231

Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore

27710

Duke University Medical Center, Durham

33612

Moffitt Cancer Center, Tampa

63110

Washington University in St. Louis, St Louis

08903

Cancer Institute of New Jersey, New Brunswick

75390-9179

UT Southwestern Medical Center, Dallas